Literature DB >> 14506637

Differential expression of perforin and granzyme B in the liver of patients with chronic hepatitis C.

Bach-Nga Pham1, Michèle Martinot-Peignoux, Dominique Valla, Sylvie Dubois, Claude Degott, Jean-François Mosnier.   

Abstract

T lymphocytes have been reported to be the predominant inflammatory cells in the liver of patients with chronic hepatitis C. On activation, CD8+ T lymphocytes can exert their cytolytic activity by releasing their granule components, notably perforin and granzyme B. The aim of the present study was to assess whether the granule cytolytic pathway was used by liver-infiltrating CD8+ T lymphocytes. Immunostaining for perforin and granzyme B was performed in 25 patients with chronic hepatitis C, according to the disease activity and their virologic status. Cells stained for perforin and for granzyme B represented 0.15% and 0.10% of the total liver-infiltrating CD8+ T lymphocytes, respectively. Perforin was expressed mainly by activated CD8+ T lymphocytes located in liver lobules. In contrast, granzyme B was expressed mainly by activated CD8+ T lymphocytes located in interface hepatitis and portal tracts. The results were similar in the different groups of patients, whatever the disease activity. In conclusion, this is the first study showing a differential expression of granule components of CD8+ T lymphocytes in the same tissue in vivo. Perforin and granzyme B may be differently expressed by liver-infiltrating CD8+ T lymphocytes, according to their localization in the different specific compartments of the liver, in patients with chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506637     DOI: 10.1016/s0046-8177(03)00244-2

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  2 in total

1.  Spred2 controls the severity of Concanavalin A-induced liver damage by limiting interferon-gamma production by CD4+ and CD8+ T cells.

Authors:  Cuiming Sun; Masayoshi Fujisawa; Toshiaki Ohara; Qiuying Liu; Chen Cao; Xu Yang; Teizo Yoshimura; Steven L Kunkel; Akihiro Matsukawa
Journal:  J Adv Res       Date:  2021-04-20       Impact factor: 10.479

2.  Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.

Authors:  Grégoire Wieërs; Nathalie Demotte; Danièle Godelaine; Pierre Van der Bruggen
Journal:  Cancers (Basel)       Date:  2011-07-18       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.